Latest Biotech News

Beckman Coulter Life Sciences announced a strategic integration with Automata that embeds Beckman liquid‑handling and analysis instruments into Automata’s LINQ automation ecosystem. Danaher...

The federal TrumpRx marketplace rollout was delayed amid increased congressional scrutiny and questions about anti‑kickback compliance, the Office of Inspector General and HHS oversight. Senators...

The FDA released a complete response letter for Corcept Therapeutics’ Cushing’s syndrome candidate and stated the agency had voiced serious concerns prior to the application submission. Corcept’s...

Origami Therapeutics announced a global collaboration with Ipsen to advance a protein‑degrader drug discovery program focused on targeted protein degradation. The agreement covers discovery and...

AstraZeneca struck a multi-partnership with China’s CSPC to bolster its weight‑management portfolio, committing $1.2 billion upfront and deal terms that could reach roughly $18.5 billion. The...

Eli Lilly unveiled a $3.5 billion manufacturing and device facility in Lehigh Valley, Pennsylvania dedicated to next‑generation obesity injectables, including retatrutide. The company said the...

Illumina completed the acquisition of SomaLogic and related assets from Standard BioTools for $350 million in cash, gaining a CLIA/CAP lab in Boulder and access to SomaScan proteomics...

Beckman Coulter Life Sciences announced a strategic partnership to integrate its liquid‑handling and genomic/cell analysis instruments into Automata’s LINQ AI‑ready automation platform. Danaher...

The FDA’s Center for Biologics Evaluation and Research granted NanoMosaic an Advanced Manufacturing Technology (AMT) designation for its Nanoneedle platform, which measures vector genome and...

Grail submitted a premarket approval application to the FDA for its Galleri multi‑cancer early‑detection blood test, drawing on performance and safety data from more than 25,000 patients in...

Quince Therapeutics reported top‑line Neat Phase III results for its erythrocyte‑encapsulated dexamethasone (eDSP) in ataxia‑telangiectasia that failed to meet the primary endpoint; the company...

Moderna announced the departure of Chief Medical Officer Jacqueline Miller after roughly a year in the role and concurrently out‑licensed a Phase‑3 rare‑disease asset to Recordati for $50 million...

The FDA released a complete response letter and asserted it had raised serious concerns with Corcept Therapeutics prior to the company’s submission for a Cushing’s syndrome therapy, contradicting...

Investigators reported that a DNA‑based immunotherapy produced substantial survival gains in clinical trials for ovarian cancer, offering the most meaningful efficacy signal in decades for the...

AstraZeneca struck multiple, high-value agreements with China’s CSPC to bulk up its obesity and metabolic portfolio while accelerating in-country R&D and manufacturing. The companies committed an...

Eli Lilly disclosed a $3.5 billion investment to build a Lehigh Valley manufacturing complex that will produce retatrutide and other next‑generation obesity injectables. The new facility is...

The FDA granted Advanced Manufacturing Technology (AMT) designation to NanoMosaic’s Nanoneedle/Tessie platform, validating a multiplex assay for direct measurement of AAV vector genome integrity...

Illumina completed its acquisition of SomaLogic and related assets for $350 million plus contingent payments, adding the SomaScan proteomic platform and a CLIA/CAP lab in Boulder to its portfolio....

Quince Therapeutics said its pivotal Phase III Neat trial of dexamethasone sodium phosphate encapsulated in autologous erythrocytes (eDSP) failed to meet its primary endpoint in...

European regulators have opened a review of Amgen’s Tavneos (avacopan) after new information raised questions about the integrity of the Advocate trial data that supported the drug’s initial...